tirzepatide cvot Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function Frontiers | Tirzepatide against obesity

References & Sources SURPASS-2 Trial (N Engl J Med) SURMOUNT-1 Trial (N Engl J Med) SELECT Trial Semaglutide CV Outcomes (N Engl J Med) SUMMIT Trial Tirzepatide HFpEF (N Engl J Med) Eli Lilly SURPASS-2 Results (Press Release) Eli Lilly SURMOUNT-1 Results (Press Release) ADA SURPASS Data Presentation SUMMIT Trial ACC Summary SELECT Trial ACC Summary Disclaimer: This information is intended for general knowledge and informational purposes only and does not constitute medical advice

Important considerations before switching GLP-1 therapy The following are important considerations before switching GLP-1 medications: Oral vs

Consider Compounded Tirzepatide Compounded tirzepatide isnt FDA approved, but its often the most affordable option if your plan denies coverage or youre paying without insurance

Mounjaro is considered a medically necessary liquid, so its exempt from the standard 3.4-ounce rule